Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02103894 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
A Phase 1 study of Parkinsons Disease (PD) and Alzheimer's Disease (AD), sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02103894: Completed Phase 1 study of Parkinsons Disease (PD) and Alzheimer's Disease (AD), sponsored by Molecular NeuroImaging.
NCT02103894 is a Phase 1 study of Parkinsons Disease (PD) and Alzheimer's Disease (AD) that has completed, run by Molecular NeuroImaging. The registered enrollment target is 16 participants, below the 119-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02103894, a Phase 1 study of Parkinsons Disease (PD) and Alzheimer's Disease (AD), has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to assess \[18F\]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease (PD) Progressive Supranuclear Palsy (PSP), chronic traumatic encephalopathy (CTE) and Frontal Temporal Dementia (FTD) and age- and gender-matched healthy subjects.
Primary Outcome
To quantitatively assess the brain uptake of \[18F\]MNI-777 (\[18F\]T807), an imaging biomarker for tau pathology in brain, using positron emission tomography (PET) in individuals with clinically diagnosed tauopathies including: Alzheimer's disease (AD), Parkinson's disease (PD), progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE) and frontal temporal dementia/Pick's disease (FTD) and healthy controls (HC).
Conditions Studied
Interventions
- DRUG [18F]T807 ([18F]MNI-777)
Study Locations (1)
Connecticut
- Molecular NeuroImaging, LLC - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
What the finished NCT02103894 record still lists
NCT02103894 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 119-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (87% lower).
The record links to 7 conditions, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which [18F]T807 ([18F]MNI-777) is the first listed.
NCT02103894 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02103894 about?
NCT02103894 is a clinical study titled "Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects". The goal of this study is to assess \[18F\]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease (PD) Progressive Supranuclear Palsy (PSP), chronic traumatic encephalopa...
What is the current status of trial NCT02103894?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-02. Estimated completion is 2016-09.
What conditions does trial NCT02103894 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD), Alzheimer's Disease (AD), Tauopathies, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE).
What interventions are being tested in trial NCT02103894?
The interventions under investigation include: [18F]T807 ([18F]MNI-777) (DRUG).
Who is sponsoring clinical trial NCT02103894?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02103894 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02103894's enrollment target sits among peer trials
16 19th of 19 higher than 1 of 19 other Parkinsons Disease (PD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinsons Disease (PD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
COMPLETED · Phase 1
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
-
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia